Results 241 to 250 of about 209,106 (262)

Advocating for Precision Neoadjuvant and Subsequent Adjuvant Therapies in Esophageal Squamous Cell Carcinoma: Evidence From a Real-World Multicenter Study. [PDF]

MedComm (2020)
Wang P, Wei X, Yu Y, Zhao Z, Ge Q, Lian J, Xing W, Li X, Li Y.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Current and future cancer staging after neoadjuvant treatment for solid tumors

Ca-A Cancer Journal for Clinicians, 2021
James Brierley, Daniel C Sullivan, Thomas P Baker   +2 more
exaly  

Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy

Cancer Cell, 2023
Suzanne L. Topalian, Kellie N Smith, Leisha Emens   +2 more
exaly  

Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial

Annals of Oncology, 2023
Y Y Hou, Z C Zeng, Z G Li
exaly  

A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction

Annals of Oncology, 2016
Fredrik Klevebro, Markus Nilsson, S Friesland   +2 more
exaly  

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

Annals of Oncology, 2018
James M. Isbell, Janis M Taube, M D Hellmann   +2 more
exaly  

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma

Annals of Oncology, 2012
Elena Tamborini, Alessandro Gronchi, B N Bui   +2 more
exaly  

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Annals of Oncology, 2019
Sherko Kuemmel, J -U Blohmer, E -M Grischke   +2 more
exaly